Trial Profile
A Multicenter Efficacy and Safety Study of Cluster of Differentiation 19 (CD19)-Targeted CART (CD19CART) Therapy for CD19 Positive Relapsed or Refractory B-cell Hematologic Malignancies (SCT019-01)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti cd19 CAR T cell therapy Innovative Cellular Therapeutics (Primary)
- Indications B-cell leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Haematological malignancies; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Innovative Cellular Therapeutics
- 06 Jun 2017 Results assessing anti-leukemic activity of CAR-T cell therapy in pediatric patients (n=11) with relapsed/refractory acute lymphocytic leukemia, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2017 Status changed to active, no longer recruiting as per results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology